The extent of lung deposition is known to be a major determinant of the therapeutic efficacy of inhaled corticosteroid. The lung deposition of extrafine aerosol of Hydrofluoroalkane-134a Beclomethasone Dipropionate (HFA-BDP) was found to be better compared with the suspension aerosol of chlorofluorocarbon beclomethasone dipropionate (CFC-BDP). The aim of this study is to evaluate pulmonary function in patients with severe asthma when CFC-BDP was changed over to HFA-BDP at half the daily dose.
This study enrolled patients (more than 20 years of age) with asthma who used high dose of CFC-BDP and whose symptom were stable with no history of exacerbation for the past year. Twenty-five adult patients with stable asthma and maintained on CFC-BDP, 800 to 2400 μg/day were recruited for this study. In addition, 36% of patients were given oral corticosteroid, 24% anti-leukotriene antagonist, 24% long β2 stimulant, 36% oral xanthine and 100% short acting β2 stimulant . Patients switched from their previous asthma treatment of CFC-BDP to HFA-BDP, at half the daily dose, while all other medications remained unchanged. Pulmonary function test was measured twice at 3 months interval during treatment with CFC-BDP and at3 months after switched over to HFA-BDP.
Switching from CFC-BDP to HFA-BDP significantly improved pulmonary function including predicted FEV1 (from 71.7% to 81.2%), predicted MMF (from 47.0% to 61.0%), predicted V50 (from 39.1% to 50.3%) and predicted V25 (from 38.2% to 48.1%).
These data suggest HFA-BDP may improve small airway of patients with severe asthma.
Asthma therapy. Inhaled corticoteroid. HFA-BDP.
Hideto Obata, None.